Last reviewed · How we verify
FECES SAMPLE
At a glance
| Generic name | FECES SAMPLE |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Blood Donor CVD 5000 (PHASE4)
- Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (NA)
- MIMICC Study in Patients With Colorectal Cancer (NA)
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (PHASE2)
- Sample Collection From Healthy Volunteers for Assay Optimization
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FECES SAMPLE CI brief — competitive landscape report
- FECES SAMPLE updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI